An updated patent review of autotaxin inhibitors (2017–present)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An updated patent review of autotaxin inhibitors (2017–present)

Published:2021-01-12 Issue:5 Volume:31 Page:421-434
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Tan Zehui¹,Lei Hongrui¹,Guo Ming¹,Chen Yuxiang¹,Zhai Xin¹

Affiliation:

1. Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, China

Funder

National Natural Science Foundation of China

Key R&D Plan of Liaoning Province in 2020

Development Project of the Ministry of Education Innovation Team

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2021.1867106

Reference106 articles.

1. Identification of Human Plasma Lysophospholipase D, a Lysophosphatidic Acid-producing Enzyme, as Autotaxin, a Multifunctional Phosphodiesterase

2. Lysophosphatidic acid as a lipid mediator with multiple biological actions

3. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells

4. Controlling cancer through the autotaxin–lysophosphatidic acid receptor axis

5. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis;European Respiratory Review;2024-04-30

2. Autotaxin inhibition attenuates the aortic valve calcification by suppressing inflammation-driven fibro-calcific remodeling of valvular interstitial cells;BMC Medicine;2024-03-14

3. Autotaxin and Lysophosphatidate Signaling: Prime Targets for Mitigating Therapy Resistance in Breast Cancer;World Journal of Oncology;2024-02

4. Tafazzin mediates tamoxifen resistance by regulating cellular phospholipid composition in ER-positive breast cancer;Cancer Gene Therapy;2023-11-07

5. Elemental exchange: Bioisosteric replacement of phosphorus by boron in drug design;European Journal of Medicinal Chemistry;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3